Daniel M. Kolansky

1.1k total citations
17 papers, 835 citations indexed

About

Daniel M. Kolansky is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Daniel M. Kolansky has authored 17 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 12 papers in Cardiology and Cardiovascular Medicine and 3 papers in Internal Medicine. Recurrent topics in Daniel M. Kolansky's work include Antiplatelet Therapy and Cardiovascular Diseases (6 papers), Lipoproteins and Cardiovascular Health (4 papers) and Coronary Interventions and Diagnostics (4 papers). Daniel M. Kolansky is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (6 papers), Lipoproteins and Cardiovascular Health (4 papers) and Coronary Interventions and Diagnostics (4 papers). Daniel M. Kolansky collaborates with scholars based in United States, Japan and Lebanon. Daniel M. Kolansky's co-authors include Daniel J. Rader, Marina Cuchel, Antoine Sarkis, Philippe Szapary, Richard E. Gregg, LeAnne T. Bloedon, Katsunori Ikewaki, Evan S. Siegelman, John S. Millar and Megan L. Wolfe and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Daniel M. Kolansky

17 papers receiving 792 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel M. Kolansky United States 10 493 258 216 179 138 17 835
Issa Alesh United States 9 519 1.1× 367 1.4× 41 0.2× 233 1.3× 130 0.9× 21 982
C. Abletshauser Germany 16 386 0.8× 264 1.0× 51 0.2× 179 1.0× 116 0.8× 36 711
Khaldoun Ben Hamda Tunisia 17 338 0.7× 337 1.3× 294 1.4× 111 0.6× 107 0.8× 61 852
Harry N. Magnani United States 16 749 1.5× 325 1.3× 49 0.2× 105 0.6× 501 3.6× 26 1.1k
Sohah N. Iqbal United States 10 804 1.6× 504 2.0× 61 0.3× 217 1.2× 18 0.1× 16 1.4k
Carmen H. Tong United States 15 323 0.7× 236 0.9× 78 0.4× 119 0.7× 181 1.3× 32 1.1k
Carlo Giammarresi Italy 11 298 0.6× 318 1.2× 63 0.3× 86 0.5× 64 0.5× 26 661
Enrico Mozzi Italy 20 524 1.1× 280 1.1× 64 0.3× 592 3.3× 80 0.6× 42 1.7k
Weifeng Shen China 14 236 0.5× 224 0.9× 108 0.5× 34 0.2× 12 0.1× 47 616
Anton Camaj United States 14 489 1.0× 381 1.5× 132 0.6× 74 0.4× 31 0.2× 37 795

Countries citing papers authored by Daniel M. Kolansky

Since Specialization
Citations

This map shows the geographic impact of Daniel M. Kolansky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Kolansky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Kolansky more than expected).

Fields of papers citing papers by Daniel M. Kolansky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Kolansky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Kolansky. The network helps show where Daniel M. Kolansky may publish in the future.

Co-authorship network of co-authors of Daniel M. Kolansky

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Kolansky. A scholar is included among the top collaborators of Daniel M. Kolansky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Kolansky. Daniel M. Kolansky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Nathan, Ashwin S., Zhi Geng, Lauren A. Eberly, et al.. (2022). Identifying Racial, Ethnic, and Socioeconomic Inequities in the Use of Novel P2Y12 Inhibitors After Percutaneous Coronary Intervention. ˜The œJournal of invasive cardiology. 34(3). 11 indexed citations
2.
Lee, Grace, Laura Conway, William Matthai, et al.. (2022). Attitudes toward pharmacogenetics in patients undergoing CYP2C19 testing following percutaneous coronary intervention. Personalized Medicine. 19(2). 93–101. 1 indexed citations
3.
Chatterjee, Saurav, Alexander C. Fanaroff, Craig S. Parzynski, et al.. (2021). Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population. JACC: Cardiovascular Interventions. 14(21). 2344–2349. 3 indexed citations
4.
Johnson, Bryce V., Christopher Domenico, Ashwin S. Nathan, et al.. (2021). Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study. ˜The œJournal of invasive cardiology. 33(12). 3 indexed citations
5.
Kanter, Genevieve P., et al.. (2021). Interventional Cardiologists’ Attitudes Towards Pharmacogenetic Testing and Impact on Antiplatelet Prescribing Decisions. Personalized Medicine. 19(1). 41–49. 1 indexed citations
6.
Tuteja, Sony, Henry A. Glick, William Matthai, et al.. (2020). Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. Circulation Genomic and Precision Medicine. 13(1). e002640–e002640. 42 indexed citations
7.
Adusumalli, Srinath, et al.. (2017). Abstract 19699: A Change in Cardiac Rehabilitation Referral Defaults From Opt-In to Opt-Out Increases Referral Rates Among Patients With Ischemic Heart Disease. Circulation. 1 indexed citations
8.
Tuteja, Sony, et al.. (2015). Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy. Current Atherosclerosis Reports. 17(5). 501–501. 4 indexed citations
9.
Raper, Anna, Daniel M. Kolansky, & Marina Cuchel. (2011). Treatment of Familial Hypercholesterolemia: Is There a Need Beyond Statin Therapy?. Current Atherosclerosis Reports. 14(1). 11–16. 17 indexed citations
10.
Gaieski, David F., Robert W. Neumar, Barry D. Fuchs, et al.. (2011). Haemodynamic management strategies are not explicitly defined in the majority of therapeutic hypothermia implementation studies. Resuscitation. 83(7). 835–839. 9 indexed citations
11.
Cuchel, Marina, LeAnne T. Bloedon, Philippe Szapary, et al.. (2007). Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia. New England Journal of Medicine. 356(2). 148–156. 416 indexed citations
12.
Mittal, Suneet, David G. Weiss, John W. Hirshfeld, Daniel M. Kolansky, & Howard C. Herrmann. (1997). Comparison of Outcome After Stenting for De Novo Versus Restenotic Narrowings in Native Coronary Arteries. The American Journal of Cardiology. 80(6). 711–715. 21 indexed citations
13.
Raper, Steven E., Mariann Grossman, Daniel J. Rader, et al.. (1996). Safety and Feasibility of Liver-Directed Ex Vivo Gene Therapy for Homozygous Familial Hypercholesterolemia. Annals of Surgery. 223(2). 116–126. 82 indexed citations
14.
Kussmaul, William G., Maurice Buchbinder, Patrick L. Whitlow, et al.. (1996). Femoral artery hemostasis using an implantable device (Angio-Seal™) after coronary angioplasty. Catheterization and Cardiovascular Diagnosis. 37(4). 362–365. 31 indexed citations
15.
Kussmaul, William G., Maurice Buchbinder, Patrick L. Whitlow, et al.. (1995). Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: Results of a randomized trial of a novel hemostatic device. Journal of the American College of Cardiology. 25(7). 1685–1692. 182 indexed citations
16.
17.
Kolansky, Daniel M., et al.. (1991). Pulmonary Embolism Presenting as Exercise-Induced Hypotension. CHEST Journal. 99(2). 500–502. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Issa Alesh Breakdown of academic impact, for papers by C. Abletshauser Breakdown of academic impact, for papers by Khaldoun Ben Hamda Breakdown of academic impact, for papers by Harry N. Magnani Breakdown of academic impact, for papers by Sohah N. Iqbal Breakdown of academic impact, for papers by Carmen H. Tong Breakdown of academic impact, for papers by Carlo Giammarresi Breakdown of academic impact, for papers by Enrico Mozzi Breakdown of academic impact, for papers by Weifeng Shen Breakdown of academic impact, for papers by Anton Camaj
Rankless by CCL
2026